Opinion|Videos|January 17, 2025
ASH 2024 Highlights: Bispecifics in Combination Therapies for B-Cell Lymphomas
Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the potential for combination therapies to be more viable in certain B-cell lymphoma subtypes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL?
- Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others? Why or why not?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
5